Events

June 29, 2020 - Events

Key Opinion Leader Webinar on IgE Antibodies to Treat Cancer

June 29, 2020 0 0 0

Lead therapeutic candidate MOv18 IgE is the world’s first IgE drug to enter clinical trials. Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, hosted a Key Opinion Leader (KOL) webinar for the...

April 28, 2020 - Events

Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting

April 28, 2020 0 0 0

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an IgE antibody as a treatment for advanced cancer London, 27 April 2020 – Epsilogen (formerly IGEM...